,PageNo,Text
0,page_0,InterStim¬Æ Amplitude Study Clinical Investigational Plan Version 2 .0 23-Aug-2018 NCT03335761
1,page_1,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ MDT17030 Version 2.0 Page 1 of 61 00HGWURQLF&RQILGHQWLDO )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWHClinical Investigation Plan Clinical Investigation Plan/Study Title InterStim¬Æ Amplitude Study Study Product Name InterStim II System Sponsor/Local Sponsor United States (Sponsor): Medtronic, Inc. 7000 Central Avenue NE Minneapolis, MN 55432 USA Europe (Local Sponsor): Medtronic International Trading S√†rl Route du Molliau 31 CH-1131 Tolochenaz, Switzerland Canada (Local Sponsor): Medtronic of Canada 99 Hereford Street Brampton, ON, L6Y 0R3 Canada 1-905-460-3800 Document Version 2.0 / 23 Aug 2018 Confidentiality Statement The information contained in this document is confidential and the proprietary property of Medtronic. Any distribution, copying, or disclosure without the prior written authorization of Medtronic is strictly prohibited. Persons to whom the informati on is disclosed must know that it is confidential and that it may not be further disclosed by them."
2,page_2,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 2 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  "
3,page_3,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 3 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  ,QYHVWLJDWRU6WDWHPHQW Participating investigators will be provided with a separate in vestigator agreement to document their obligations and commitment with respect to study conduct."
4,page_4,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 4 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  7DEOHRI&RQWHQWV  ,QYHVWLJDWRU6WDWHPHQW   7DEOHRI&RQWHQWV    *ORVVDU\     6\QRSVLV    ,QWURGXFWLRQ    %DFNJURXQG    3XUSRVH    2EMHFWLYHVDQG(QGSRLQWV    2EMHFWLYHV   5.1.1. Primary Objective ...................................... ............................................................... ............. 18 5.1.2. Seconda ry Objective..................................... ............................................................... .......... 18 5.1.3. Addition al Measu res .................................... ............................................................... .......... 18  6WXG\'HVLJQ    'XUDWLRQ    5DWLRQDOH    3URGXFW'HVFULSWLRQ    *HQHUDO    0DQXIDFWXUHU    ,QWHQGHG3RSXODWLRQ    3URGXFW5HWXUQ    3URGXFW$FFRXQWDELOLW\    6HOHFWLRQRI6XEMHFWV    6WXG\3RSXODWLRQ    6XEMHFW(QUROOPHQW    ,QFOXVLRQ&ULWHULD    ([FOXVLRQ&ULWHULD    6WXG\3URFHGXUHV    6FKHGXOHRI(YHQWV  "
5,page_5,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 5 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH    6XEMHFW6FUHHQLQJ    3ULRUDQG&RQFRPLWDQW2$%0HGLFDWLRQV   6XEMHFW&RQVHQW    5DQGRPL]DWLRQDQG7UHDWPHQ W$VVLJQPHQW   2$%0HGLFDWLRQ&RPSOLDQFH   $VVHVVPHQWRI(IILFDF\     $VVHVVPHQWRI6DIHW\     5HFRUGLQJ'DWD    'HYLDWLRQ+DQGOLQJ   6XEMHFW:LWKGUDZDORU'LVFRQWLQXDWLRQ    5LVNVDQG%HQHILWV    3RWHQWLDO5LVNV    5LVNV2XWOLQHGLQWKH,QVWUXFWLRQVIRU8VH ,)8    3RWHQWLDO%HQHILWV    5LVN%HQHILW5DWLRQDOH   $GYHUVH(YHQWVDQG'HYLFH'HILFLHQFLHV   'HILQLWLRQV&ODVVLILFDWLRQV   5HSRUWRI$GYHUVH(YHQWV   'HYLFH'HILFLHQFLHV   'HDWKV    'DWD5HYLHZ&RPPLWWHHV   6WDWLVWLFDO'HVLJQDQG0HWKRGV   *HQHUDO6WDWLVWLFDO& RQVLGHUDWLRQV   13.1.1 Study Sample Size Justification ........................ ............................................................... ... 43 13.1.2 Description of demographic and baseline variables ...... ................................................... 44 13.1.3 Center Pooling ......................................... ............................................................... ........... 44 13.1.4 Missi ng Data ........................................... ............................................................... ............ 44 13.1.5 Interim Analysis ....................................... ............................................................... ........... 44 13.1.6 Reports ................................................ ............................................................... ............... 44 13.1.7 Study S uccess .......................................... ............................................................... ............ 44 13.1.8 Subgroup Analyses ...................................... ............................................................... ....... 44"
6,page_6,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 6 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  13.1.9 Patient Populations .................................... ............................................................... ........ 44  3ULPDU\2EMHFWLYH   6HFRQGDU\2EMHFWLYH    $GGLWLRQDO0HDVXUHV    (WKLFV    6WDWHPHQW V RI&RPSOLDQFH   3ULQFLSDO,QYHVWLJDWRU 2YHUVLJKW   6WXG\$GPLQLVWUDWLRQ    6SRQVRU    6LWH6HOHFWLRQ    &OLQLFDO7ULDO$JUHHPHQW    &XUULFXOXP9LWDH    0RQLWRULQJ    0HGWURQLF5HSUHVHQWDWLYH5ROH    'DWD0DQDJHPHQW   'LUHFW$FFHVVWR6RXUFH'DWD'RFXPHQWV     &RQILGHQWLDOLW\    /LDELOLW\    &,3$PHQGPHQWV   5HFRUG5HWHQWLRQ    3XEOLFDWLRQDQG8VHRI,QIRUPDWLRQ    6XVSHQVLRQRU(DUO\7HUP LQDWLRQ   5HIHUHQFHV    $SSHQGLFHV    $SSHQGL[$ $GGLWLRQDO,QIRU PDWLRQIRU6LWHV   $SSHQGL[% ,QVWLWXWLRQDO5HYLHZ%RDUGV(WKLFV&RPPLWWHHV   $SSHQGL[& 3DUWLFLSDWLQJ,QYHVWLJDWRUVDQG,QVWLWXWLRQV   $SSHQGL[' ,QIRUPHG&RQVH QW0DWHULDOV   9HUVLRQ+LVWRU\  "
7,page_7,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 7 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  *ORVVDU\ TERM DEFINITION ADE Adverse Device Effect ADVANCED EVALUATION Therapy evaluation using InterStim Tined Lead AE Adverse Event AT As Treated AWC Adjusted Worst Case BASIC EVALUATION Therapy evaluation using tempo rary Test Stimulation Lead CC Complete Case CFR Code of Federal Regulations CIP Clinical Investigational Plan eCRF Electronic Case Report Form FAS Full Analysis Set FDA Food and Drug Administration GCP Good Clinical Practice HIPAA Health Insurance Portability and Accountability Act ICF Informed Consent Form IDE Investigational Device Exemption IRB Institutional Review Board LOCF Last Observation Carried Forward NPU Neuro Programmer Upload OAB Overactive Bladder ICIQ-OABqol International Consultation on Incontinence Modular Questionnaire - Overactive Bladder Symptoms Quality of Life Questionnaire PNE Peripheral Nerve Evaluation QoL Quality of Life ORACLE RDC Oracle Remote Data Capture REPORTABLE ADVERSE EVENTS AND DEVICE DEFICIENCIES Serious, device-related, procedure-related, therapy-related adverse events and all device deficiencies will be considered reportable for this study SADE Serious Adverse Device Effect SAE Serious Adverse Events SAP Statistical Analysis Plan SENSORY THRESHOLD Sensory threshold is defined as the lowest amplitude where the subject first perceives sens ation of the stimulation in the perineum, perianal, vaginal, or any location deemed appropriate by the investigator while in a seated position. SNM Sacral Neuromodulation"
8,page_8,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 8 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  TERM DEFINITION USADE Unanticipated Serious Adverse Device Effect UF Urgency Frequency UI Urinary Incontinence UUI Urinary Urge Incontinence US United States UTI Urinary Tract Infection"
9,page_9,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 9 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  6\QRSVLV Title InterStim Amplitude Study Clinical Study Type Post-Market, On-Label Product Name InterStim II (Model 3058) and In terStim Quadripolar Lead Model 3889-XX (hereinafter referred to o nly as the tined lead or Mode l 3889) with commercially-approved acc essories. Either the InterS tim Tined Lead Model 3889 or the te mporary Test Stimulation Lead ( the lead is sold via Models 305 901, 305906 or 309101, hereinafter referred to only as the Test Stimulation Le ad) may be used for the therapy evaluation. In the rest of this document, ‚Äúa dvanced evaluation‚Äù will refer to therapy evaluation using InterStim Tined Lead and ‚Äúbasic evalua tion‚Äù will refer to therapy evaluation using temporary Test Stimulati on Lead. Sponsor Medtronic, Inc. Indication under investigation The indication under investigati on is overactive bladder (OAB). There are no investigational dev ices used in this study, all st udy products will be used in accordance with the product labeling. Investigation Purpose To assess the effect of three different amplitude settings (50% of sensory threshold, 80% of sensory threshold and s ensory thresho ld) on urinary urge inco ntinence (UUI). Sensory threshold is defined as the amplitude where the subject first perceives the sensation of the s timulation in the perineum, per ianal, vaginal, or any location deemed appropriate by the investigator while in a seated position. Product Status The InterStim II system is comme rcially approved for the treat ment of patients with OAB. Primary Objective To explore the effect of three different amplitude settings on urinary urge incontinence (UUI). Secondary Objective To characterize results from the ICIQ-OABqol questionnaire for the three different amplitude settings. Additional Measures to summarize safety for the three different a mplitude settings. Study Design This is a prospective, randomize d, multicenter, single-blinded study to explore the efficacy and quality of life (QoL) of 3 different a mplitude settings. The study will be condu cted at approximately 20 cent ers in the United States, Canada and Europe. Enrolled subjects who meet all eligibility criteria, have succe ssful therapy evaluation (50% improvement in UUI or UF voiding symptoms, or return to normal voiding of < 8 voids per day for UF"
10,page_10,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 10 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  subjects) and qualify for a neuros timulator device implant in t he study will be randomized to one of th e 3 amplitude settings. Subject s will complete enrollment/baseline visi ts, lead implant, therapy eval uation, neurostimulator device implant, r andomization, 1-week follow-up visit, 6-week follow-up visit and 12-week follow-up visit. The total study duration for a s ubject is approximately 16 week s. Randomization Subjects must meet all eligibilit y criteria and demonstrate a s uccessful therapy evaluation prior to being randomized to one of three th erapy amplitudes: sensory threshold, 50% of sensory threshold or 80% of sensory threshold. Sample Size This study requires approximatel y 42 implanted and randomized subjects with 12-week follow-up to be analyzed for the primary objective. Approximately 60 subjects are estimated to be enrol led in the study with approximately 48 randomized; however, these numbers may vary to ensure that a minimum of 42 implanted subjects complete the study. Inclusion/Exclusion Criteria Inclusion Criteria: 1.Primary diagnosis of urinary urge incontinence (UUI) as demonstrated on a 3-day baseline voiding diary demonstrating at least 3 UUI episodes 2.Female subjects 18 years of age or older 3.Candidate for InterStim Lead Placement 4.Willing and able to accurately complete voiding diaries, questionnaires, attend visits, and comply with the study protocol (which includes maintenance of InterStim II programming settings over the course of the study) 5.Willing and able to provide signed and dated informed consent 6.Willing to maintain current reg imen (dosage and frequency) of any overactive bladder (OAB) medication Exclusion Criteria: 1.Have neurological conditions such as multiple sclerosis, clinically significant periphe ral neuropathy or spinal cord injury 2.History of diabetes unless th e diabetes is well-controlled through diet and/or medications"
11,page_11,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 11 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  3.Symptomatic urinary tract infection (UTI) 4.Have primary stress incontinence or mixed incontinence where the stress component ove rrides the urge component 5.Treatment of urinary symptoms with botulinum toxin in the past 9 months or any plan to have botulinum toxin treatment during the study 6.Implanted with a neurostimulator, pacemaker, or defibrillator 7.Have knowledge of planned MR Is, diathermy, microwave exposure, high output ultrasonic exposure, or RF energy exposure not included within the scanning conditions provided with the MRI Guide lines for InterStim Therapy 8.Women who are pregnant or planning to become pregnant 9.Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements Currently enrolled or planning to enroll in a potentially confounding clinical study durin g the course of the study (co- enrollment in concurrent studies is only allowed when documented pre-approval is obtained from the Medtronic study manager (or designee) Study Procedures and Assessments Study Visits: 1.Enrollment / Baseline 2.Tined Lead or temporary Test Stimulation Lead Implant 3.Therapy Evaluation 4.Tined Lead (if applicable) / Neurostimulator Device Implant (randomization procedures) 5.One Week Follow-up Visit 6.Six Week Follow-up Visit 7.Twelve Week Follow-up Visit Enrollment/Baseline Subjects are considered enrolled at the time the study-specific informed consent is si gned. Each subject must meet all the inc lusion and no exclusion criteria to be eligible to participate in the study. At the enrollment/baseline visit, d ata will be gathered from subje cts including relevant medical history and concomitant OAB medicati on. Subjects will complete the following questionnaire:"
12,page_12,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 12 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  xOveractive Bladder Symptoms Quality of Life Questionnaire (ICIQ-OABqol) The voiding diary will be explai ned and given to the subject to be completed for 3 consecutive days . The 3-day voiding diary must be completed along with confirmation that the subject is not pregn ant or planning to become pregnant during participation in the trial, as part of the assessment for s tudy eligibility. Tined Lead or temporary Test Stimulation Lead Implant If using basic evaluation, the temporary Test Stimulation Lead should be placed in accordance with the InterStim system Test Stimulat ion Lead Kit and Test Stimulation Lead Technical Manual. If using advanced evaluation, the InterStim tined lead should be placed in accordance with the InterStim Therapy Model 3889 Lead Implant Manual. For both advanced and basic eval uation, throughout the study, unilateral stimulation is required. Settings may be set pe r Investigator discretion during the ther apy evaluation period. Any reportable adverse events/device deficienci es will be documented and repor ted. Therapy Evaluation The therapy evaluation period should be conducted in accordance with the InterStim II System Labeling using the Verify¬Æ Externa l Neurostimulator. The therapy evaluation period must not exceed either 14 days if using InterStim tined lead, or 7 days if usin g the temporary Test Stimulation Lead or the approved duration in the"
13,page_13,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 13 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  commercially available labeling in the respective country. A 3- day voiding diary will be completed t owards the end of the therapy evaluation period . A minimum of a 50% improvement in voiding symptoms (either UUI or UF), or return to normal voiding of < 8 voids per day for UF subjects, is requi red in order to qualify for a neurostimulator implant in the study. Any reportable adverse events/ device deficiencies will be documented and reported. Tined Lead (if applicable) / Ne urostimulator Device Implant (randomization procedures) Once the subject qualifies for the neurostimulator device impla nt, site personnel may proceed with the Neurostimulator Device Implant V isit and randomization procedures. If a subject does not qualify fo r the neurostimulator device implant, they will be exited from the st udy. For subjects who qualify for devi ce implant following a success ful basic evaluation, the InterStim tined lead should be placed in accordance with the InterStim Therapy Model 3889 Lead Implant Manual. At the time of the neurostimulator device implant, site personn el will obtain a randomization assignment to randomize each subject to one of the following therapy amplit udes: sensory threshold, 50% of sensory threshold or 80% of sens ory threshold. Subjects are bl inded to their randomized setting. All measures should be taken to ensure that the subject does not become unblinded to their randomizati on throughout the study. Subjects will be implanted with the Neurostimulator in accordan ce with the InterStim Therapy Inter Stim II Model 3058 Neurostimula tor Implant Manual. After the device implant is complete, it is required that subje cts be programmed to 14 hertz (Hz), 210 Œºs pulse width (pw) and contin uous stimulation for the duration of the study. During programming throughout the study, the subjec t‚Äôs sensory thre shold amplitude will be determined by following this protocol: start at 0.05 volts (V) and increase voltage in 0.05 V increments until the subject reports sensation. Prior to discharge, t he amplitude at each electrode configuration that elicits a sen sory response must be determine d in seated positions. As part of the programming, impedance checks should be compl eted during each study visit."
14,page_14,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 14 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  Following determination of sensor y threshold (seated position), amplitude will be programmed based on the assigned randomizatio n of sensory threshold, 80% of sen sory threshold, or 50% of senso ry threshold. Subjects will be allowe d to adjust amplitude +/- 0.0 5 V during the study. Therapy amplit ude will remain at this level (¬± 0.05 V) until the next follow-up visit or programming session. A ny reportable adverse events will be documented and reported. 1-Week Follow-up Visit At the 1-week follow-up visit, any reportable adverse events, d evice deficiencies and will be collected. Prior to the completion of the v isit, the amplitude at each ele ctrode configuration that elicits a sen sory response must be determine d in seated positions. Following determination of sensory threshold, amplitude will be programmed based on the assigned randomization. Over the course of the study any changes to programmed paramete rs (amplitude, PW, rate or cycling) outside of the allowable setti ngs in the study will be considered a pro tocol deviation; however, sub jects will be encouraged to continue in the study. The voiding diary will be explai ned and given to the subject to be completed approximately 3 days p rior to the 6-week follow-up vi sit. 6-Week Follow-up Visit At the 6-week follow-up visit, t he subject‚Äôs voiding diary comp leted during the previous perio d will be collected. reportable adverse events, device deficiencies and other information will be collected from the subject.  Prior to the completion of the v isit, the amplitude at each ele ctrode configuration that elicits a sen sory response must be determine d in seated positions. Following determination of sensory threshold, amplitude will be programmed based on the assigned randomization using the sensory threshold in the seate d position."
15,page_15,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 15 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  The voiding diary will be explai ned and given to the subject to be completed approximately 3 days prior to the 12-week visit. 12-Week Follow-up Visit At the 12-week follow-up visit, the subject‚Äôs voiding diary com pleted during the previous perio d will be collected. reportable adverse events, de vice deficiencies and other information will be collected fro m the subject. Prior to the completion of the visit, the ampl itude at each electrode config uration that elicits a sensory response must be determined in seated positions. Subjects will complete the following questionnaires: xICIQ-OABqol  The subject is exited from the study after the 12-week follow-u p visit is complete. Programming param eters after the subject has completed the study are at the Investigator‚Äôs discretion. Unscheduled Visit If an unscheduled visit is needed for any device-related reason , the amplitude at each electrode conf iguration that elicits a sensor y response must be determined in seated positions. Following determination of sensor y threshold, amplitude will be programmed based on the assigned randomization using the sensor y threshold in the seated position. In addition to programming activities, , reportable adverse events and de vice deficiencies will be colle cted. Surgical Revision If a surgical revision is required after the full system implan t, the subject will be exited from the study. Safety Assessments Safety will be evaluated by the collection of reportable advers e events and device deficiencies. Statistics This study will explore the effe ct of three different amplitude settings (50% of sensory threshold, 80% of sensory threshold and sensory threshold) on UUI episodes per day. Change of average UUI epi sodes per day at 12-week follow-up from baseline will be assessed und er each amplitude setting."
16,page_16,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 16 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  This study requires approximatel y 42 implanted and randomized subjects with 12-week follow-up to be analyzed for the primary objective. Approximately 60 subj ects are estimated to be enroll ed in the study with approximately 48 randomized; however, these numbers may vary to ensure that a minimum of 42 implanted subjects complete the study. Assuming a mean reduction between 1.8 to 2.3 UUI episodes per d ay with a standard deviation of 2.2 to 2.7 UUI episodes per day is observed, with …≤—Åœ¨Õòœ¨œ±∆ö«Å≈Ω -sided and using a t-statistic to construct the confidence interval, a sampl e size of 14 subjects would hav e a precision of 1.56 UUI episodes p er day for the assumption with a standard deviation of 2.7. Precision is defined as one-half of the confidence interval (also known as the distance from the confid ence limits to the mean). This precision is less than our lowest ass umed treatment effect (1.8 UUI), so it is expected that the lower 95 % CI will be greater than 0 for all treatm ent arms, even in the scenario when the largest standard deviation was applied. This sample size calculation intends to be sufficient to explor e the effect of each of three amplitude settings on UUI; however, the sample size is not sufficient for between group comparisons."
17,page_17,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 17 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  ,QWURGXFWLRQ  %DFNJURXQG One of the most common patient co mplaints about sacral neuromod ulation (SNM) for overactive bladder (OAB) is unwanted or uncomfortable stimulation.1,2 It is often assumed that higher amplitude stimulation will provide better efficacy, but there is a lack o f clinical evidence regarding amplitude effects of SNM for OAB. However, there is some evidence that SN M for fecal incontinence is effective at sub-sensory threshold/amplitude.3 This study will explore whether lower amplitude stimulation ca n provide improved symptom control when compared to baseline. P otential effects of lower amplitude may include changes in or sustai ned efficacy, or reduced patien t complaints due to uncomfortable stimulation. This feasibility study will provide an initial und erstanding of various amplitude stimulation settings and the impact on symptoms. The effect of amplitude on SNM therapy efficacy is not well cha racterized clinically for either OAB4 or fecal incontinence5. However, preclinical data suggest the effect of SNM is amplit ude-dependent. Using the rodent model of rhythmic bladder contractions (RBC), Su et al (2012) showed th at increasing amplitude of spinal nerve stimulation from motor threshold ampl itude to 3x motor threshold resulted in inhibition of bladder contractio ns by 20 to 90%, respectively.6 Similarly, using the RBC model in cats, Snellings and Grill ( 2012) showed that stimulation of the of th e pudendal nerves inhibited the frequency of contractions and increased bladder capacity at 0.8, 1, and 2 times motor threshold in an intensity- dependent manner.7 Finally, stimulation of tibial nerve and dorsal nerve of the penis produced an amplitude-dependent inhibition of bladder contractions in the r odent.8 The sum of these studies suggest that the effect of neurom odulation on bladder function is amplitude-dependent. Duelund-Jakobsen et al (2013) demonstrated that there was no si gnificant difference in reduction of fecal incontinent episodes when subjects were programmed to 50% , 75%, and 100% of sensory ∆ö≈ö∆åƒû∆ê≈ö≈Ω≈ØƒöÕæ≈∂—Åœ≠œµÕøÕò3 In a recent clinical study u sing fMRI, Gill et al demonstrat ed a stimulation amplitude- dependent response in brain acti vity in 6 patients receiving su b-sensory, sensory, and supra-sensory SNM.6 These studies suggest SNM efficacy at sub-sensory amplitudes. Given the preclinical data showing an amplitude-dependent effec t of neuromodulation on bladder function and the clinical data de monstrating a therapeutic effe ct of sub-sensory amplitude, it is important to understand the effica cy of SNM at different subsen sory and sensory threshold amplitudes. 3XUSRVH The purpose of this prospective, multicenter, randomized, singl e-blind feasibility study is to explore the efficacy and quality of life unde r 3 different amplitude settin gs (sub-sensory amplitudes of 50% and 80% of sensory threshold and sensory threshold). Efficacy will be characterized with change from baseline"
18,page_18,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 18 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  through 12 weeks in UUI episodes and patient reported outcomes. Quality of life will be characterized with the ICIQ-OABqol Questionnair e at baseline and 12 weeks. Su bject participation will last approximately 16 weeks followin g the enrollment visit. Subject s are exited from th e study after the 12- week follow-up visit is completed. 2EMHFWLYHVDQG(QGSRLQWV 2EMHFWLYHV 3ULPDU\2EMHFWLYH The primary objective in the stu dy is to explore the effect of three different amplitude settings (50% of sensory threshold, 80% of sensory threshold and s ensory thresho ld) on number of UUI episodes per day 6HFRQGDU\2EMHFWLYH Secondary objective of this stu dy is quality of life (ICIQ-OABq ol) for the three different amplitude settings. $GGLWLRQDO0HDVXUHV Additional measures include: xSafety   6WXG\'HVLJQ This is a prospective, multicent er, randomized, single-blind, f easibility study to explore the efficacy and quality of life of 3 different a mplitude settings in patients w ith UUI. Subjects will remain blinded to their assigned randomization for the duration of the study. Eligible subjects will sign a study-specific informed consent f orm (ICF). Following verification of eligibility criteria, subjects will go throug h therapy evaluation with the InterStim II System. After qualifying for the device implant, the subject will proceed with a neurostimulator device implant and randomization procedures. Subjects will be ra ndomized to one of the three a mplitude settings: 50% of sensory threshold, 80% of sensory thresh old and sensory threshold."
19,page_19,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 19 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  Study requirements, including voiding diaries, quality of life questionnaires , and safety assessments will be completed as required in Figure 9-1: Study Visits. The study is expected to last approximately 16 weeks per subject following the enrollment vis it. Subjects will be exited from the study after the 12-week follow-up visit is complete. A minimum of forty-two implanted subjects (at least 14 subjects per arm) who have completed the 12- week follow-up visit are needed t o assess the study primary obj ective. To account for screen failures, therapy evaluation conversion rate and loss to follow-up or mis sing data, it is anticipated that approximately 60 subjects will be consented and approximately 4 8 subjects will be implanted/randomized. The study will be conducted at a pproximately 20 sites in the Un ited States, Canada, and Europe. This is an on-label, post-market study of an approved system. All subjects enrolled in the study will qualify under the approved indication for the InterStim II Syst em. 'XUDWLRQ Study subjects will be enrolled and will complete enrollment an d baseline assessments to determine eligibility for an InterStim lead implant procedure. Subjects that do not meet eligibility criteria and/or qualify for a neurostimulator dev ice implant will be exited fro m the study. All en rolled subjects that qualify for the study (meet all in clusion and no exclusion crit eria) will be randomized and undergo an InterStim II device implant procedure. Post implant, subjects will be required to attend the 1-week follow-up visit (window +/- 3 da ys), 6-week follow-up visit (wi ndow +/- 7 days), and 12-week follow-up visit (window +/- 7 days). The visits are expected to occur ov er approximately 16 weeks starting at the enrollment visit. The estimated study duration, fr om first subject enrollment to last subject visit, is expected to last approximately 18 months. The completion of the study is define d as the approval of the Final Study Report and closure of all sites. 5DWLRQDOH While there is extensive literatur e on the safety and efficacy of SNM in patients with OAB, there is a paucity of published literature regarding amplitude programming , specifically programming to levels below sensory threshold. The purpose of this study is to expl ore the effect of sensory and sub-sensory stimulation using the InterStim II System. The InterStim II Sy stem is approved and will be used in accordance with commercially ava ilable product labeling for the specific geography."
20,page_20,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 20 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  3URGXFW'HVFULSWLRQ  *HQHUDO There are no investigational devices used in this study. The study will be conducted in th e US, Canada, and Europe, coun tries where the Neurostimulator Model 3058 (InterStim II), ti ned lead model 3889 a nd the temporary Te st Stimulation Lead (sold via Models 305901, 305906 or 309101, hereinafter referred to only as the t emporary Test Stimulation Lead)are commercially available as part of the InterStim system (for th e treatment of OAB). The 3 amplitude settings under investigation are within the commercially-approv ed programming parameters. For the present study, the subject will be able to turn off the stimula tor or decrease amplitude if needed for safety reasons, and to make mino r increases to amplitude (if de sired). Labeling will be provided in acc ordance with local language and regulatory requirements. 0DQXIDFWXUHU The products used in this study, identified in Section 7.1, are manufactured by Medtronic, Inc. and are approved for use in treating patients with OAB. Manufacturer Medtronic, Inc. 710 Medtronic Parkway Minneapolis, MN 55432-5604 USA ,QWHQGHG3RSXODWLRQ The study will enroll patients w ith a diagnosis of OAB and asso ciated symptoms of UUI. All subjects implanted must be candidates for InterStim Therapy. 3URGXFW5HWXUQ Since all products are commercia lly available, standard commerc ial processes should be used to return product (as applicable). 3URGXFW$FFRXQWDELOLW\ All product used in the study are commercially available; there fore, no product accountability will be required for the study."
21,page_21,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 21 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  6HOHFWLRQRI6XEMHFWV  6WXG\3RSXODWLRQ The intended study population is subjects diagnosed with OAB an d associated signs and symptoms of UUI. 6XEMHFW(QUROOPHQW  Subjects are considered enrolled at the time the study-specific ICF is signed. Each subject must meet all the inclusion criteria and no ex clusion criteria to be eligible to participate in this study. Any subject not meeting eligibility criteria will be excluded from study partic ipation. Site personnel must complete logs related to recruitment and enrollm ent as required by the study. ,QFOXVLRQ&ULWHULD To be eligible to participate in the study, a subject must meet all the following inclusion criteria: 1.Primary diagnosis of urinary urg e incontinence (UUI) as demonst rated on a 3-day baseline voiding diary demonstrating at least 3 UUI episodes 2.Female subjects 18 years of age or older 3.Candidate for InterStim Lead Placement 4.Willing and able to accurately complete voiding diaries, questi onnaires, attend visits, and comply with the study p rotocol (which includes maintenance of I nterStim II programming settings over the co urse of the study) 5.Willing and able to provide signed and dated informed consent 6.Willing to maintain current regim en (dosage and frequency) of a ny overactive bladder (OAB) medication ([FOXVLRQ&ULWHULD A potential subject who meets an y of the following criteria wil l be excluded from participating in the study: 1.Have neurological conditions such as multiple sclerosis, clinic ally significant peripheral neuropathy or spinal cord injury 2.History of diabetes unless the diabetes is well-controlled thro ugh diet and/or medications"
22,page_22,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 22 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  3.Symptomatic urinary tract infection (UTI) 4.Have primary stress incontinence or mixed incontinence where th e stress component overrides the urge component 5.Treatment of urinary symptoms with botulinum toxin in the past 9 months or any plan to have botulinum toxin treatment during the study 6.Implanted with a neurostimulator, pacemaker, or defibrillator 7.Have knowledge of planned MRIs, diathermy, microwave exposure, high output ultrasonic exposure, or RF energy exposure not included within the scannin g conditions provided with the MRI Guidelines for InterStim Therapy 8.Women who are pregnant or planning to become pregnant 9.Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requir ements 10.Currently enrolled or planning to enroll in a potentially confo unding clinical study during the course of the study (co-enrollmen t in concurrent studies is onl y allowed when documented pre- approval is obtained from the Me dtronic Study Manager (or desig nee) 6WXG\3URFHGXUHV The study schedule, procedures, and methods of assessment are d efined in detail to enable compliance with the required activities, and to ensure that the resulting data meet the criteria for evaluability. See Figure 9-1 for Study Visit. Ele ctronic case report forms (eCRF ) will be provided for use in collecting data for all subjects; the pertinent e CRFs along with the applicable source documentation will be completed for each subject. The following study visits will be conducted: 1.Enrollment / Baseline 2.Tined Lead or temporary Test Stimulation Lead Implant 3.Therapy Evaluation 4.Tined Lead (if applicable) / Neurostimulator Device Implant (ra ndomization procedures) 5.One Week Follow-up Visit 6.Six Week Follow-up Visit 7.Twelve Week Follow-up Visit"
23,page_23,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 23 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH   6FKHGXOHRI(YHQWV Enrollment/Baseline Subjects are considered enrolled at the time the study-specific informed consent is signed. Each subject must meet all the inclusion and no exclusion criteria to be eli gible to participate in the study. At the enrollment/baseline visits, data will be gathered from subjects including relevant medical and concomitant OAB medication histo ry. Enrollment and Baseline Vi sit requirements wil l occur at separate visits. Subjects will complete the following questionnaire: xOveractive Bladder Symptoms Qualit y of Life Questionnaire (ICIQ -OABqol) The voiding diary will be explai ned and given to the subject to be completed for 3 consecutive days. The 3-day voiding diary must be comp leted along with confirmation t hat the subject is not pregnant or planning to become pregnant during participation in the trial, as part of the assessment for study eligibility. Any reportable adverse events f ollowing informed consent will be documented and reported. Device deficiencies will be collected beginning at the time of the fir st exposure to the InterStim II System. Tined Lead or temporary Test Stimulation Lead Implant If using basic evaluation, the temporary Test Stimulation Lead should be placed in accordance with the InterStim System Test Stimulatio n Lead Kit and Test Stimulation Lead Technical manual. If using advanced evaluation, the InterStim tined lead (model 3 889) should be placed in accordance with the InterStim Therapy Mode l 3889 Lead Implant Manual."
24,page_24,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 24 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH   Settings may be set pe r Investigator discretion during the ther apy evaluation period and will be documented. Any reportable adverse events/device deficiencie s will be documented and reported. Therapy Evaluation The therapy evaluation period sh ould be conducted in accordance with the InterStim II System Labeling. The therapy evaluation period mus t not exceed either 14 days if using InterStim tined lead or 7 days if using the temporary Test Stimulat ion Lead as defined by current labeling, or a new approved duration in an updated commercially availabl e labeling in the respective co untry. A 3-day voiding diary will be completed towards the end of t he therapy evaluation period . A minimum of a 50% improvement in UUI or UF voiding symptoms, or re turn to normal voiding of < 8 voids per day for UF subjects, is required in order to qualify for a neurostimulator implant in the study. Settings used during therapy evaluation will be documented during this visit. Any reportable adverse events/device deficiencies will be documented and reported. Tined Lead (if applicable) / Neur ostimulator Device Implant (ra ndomization procedures) Once the subject qualifies for the neurostimulator device impla nt, site personnel may proceed with the neurostimulator device implant and randomization procedures. I f a subject does not qualify for the neurostimulator device implant, they will be exited from the st udy. For subjects who qualify for dev ice implant following a success ful basic evaluation, the InterStim tined lead should be placed in accordance with the InterStim Therapy Model 3889 Lead Implant Manual. At the time of the neurostimulator device implant, site personn el will obtain a randomization assignment to randomize each subj ect to one of the following th erapy amplitudes: sensory threshold, 50% of sensory threshold or 80% of sensory threshold. Subjects are blinded to their randomization. All measures should be taken to ensu re that the subject does not be come unblinded to their randomization throughout the study. Subjects will be implanted with t he Neurostimulator in accordan ce with the InterStim Therapy InterStim II Model 3058 Neurostimul ator Implant Manual. After the device implant is complete, it is required that subje cts be programmed to 1 4 hertz (Hz), 210 Œºs pulse width (pw) and continuous s timulation for the duration of the study. During programming, the subject‚Äôs sensory threshold amplitude will be determined by fol lowing this protocol: start at 0.05 volts (V) and increase voltage using fine resolution in 0.05 V increm ents until the subject reports sensation."
25,page_25,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 25 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  Prior to discharge, the amplitud e at each electrode configurati on that elicits a sensory response must be determined in seated positions . To determine sensory threshol d, each electrode (0,1,2,3) will be programmed as t he cathode (negative) in a bip olar configuration in a systematic fashion. Following determination of sens ory threshold, amplitude will be programmed based on the assigned randomization of sensory threshold, 80% of sensory threshold, o r 50% of sensory threshold using the sensory threshold in a seated po sition. As part of the program ming, impedance checks should be completed. Upon completion of programming, data will be collect ed via a programming printout or Neuro Programmer Upload (NPU). Subjects will be allowed to adj ust amplitude +/- 0.05 V during the study. Therapy amplitude will remain at this level (¬± 0.05 V) until the next follow-up visit or prog ramming session. Any reportable adverse events/device deficiencies will be document ed and reported. 1-Week Follow-up Visit At the 1-week follow-up visit, any reportable adverse events, d evice deficiencies will be collected. During the visit, the subject‚Äôs sensory threshold amplitude wil l be captured by following this protocol: start at 0.05 V and increase voltage using fine resolution in 0 .05 V increments until the subject reports sensation. Prior to the comple tion of the visit, the amplitu de at each electrode configuration that elicits a sensory response must be determined in seated posit ions. To determine sensory threshold, each electrode (0,1,2,3) will be programmed as the cathode (negative) in a bipolar configuration in a systematic fashion. Following determination of sensory threshold amplitude, amplitu de will be programmed based on the assigned randomization using sensory threshold in a seated posi tion. Subjects will be allowed to adjust amplitude +/- 0.05 V during the study. As part of the programm ing, impedance checks should be completed. Upon completion of programming, data will be collect ed via a programming printout or NPU. Over the course of the study any changes to programmed paramete rs (amplitude, PW, rate or cycling) outside of the allowable setting s in the study will be consider ed a protocol deviation; however, subjects will be encouraged to continue in the study. The voiding diary will be explai ned and given to the subject to be completed approximately 3 days prior to the 6-week follow-up visit."
26,page_26,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 26 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  6-Week Follow-up Visit At the 6-week follow-up visit, t he subject‚Äôs voiding diary comp leted during the previous period will be collected. reportable adverse events, device deficiencies and other information will be collect ed from the subject.  During the visit, the subject‚Äôs sensory threshold amplitude wil l be captured by following this protocol: start at 0.05 V and increase vol tage using fine resolution in 0 .05 V increments until the subject reports sensation. Prior to the comple tion of the visit, the amplitude at each electrode configuration that elicits a sensory response must be deter mined in seated positions. To determine sensory threshold, each electrode (0,1,2 ,3) will be programmed as the c athode (negative) in a bipolar configuration in a systematic fashion. Following determination of sens ory threshold, amplitude will be programmed based on the assigned randomization using the sensory th reshold in the seated positio n. Subjects will be allowed to adjust amplitude +/- 0.05 V during the study. As part of the program ming, impedance checks should be completed. Upon completion of p rogramming, data will be collec ted via a programming printout or NPU. The voiding diary will be explai ned and given to the subject to be completed approximately 3 days prior to the 12-week visit. 12-Week Follow-up Visit At the 12-week follow-up visit, the subject‚Äôs voiding diary com pleted during the previous period will be collected. reportable adverse events, device deficiencies and other information will be collected fro m the subject. During the vis it, the subject‚Äôs sensory threshold will be captured by following this protoc ol: start at 0.05 V and increa se voltage in 0.05 V increments until the subject reports sensation. Prio r to the completion of the visi t, the amplitude at each electrode configuration that elicits a sen sory response must be determine d in seated positions. To determine sensory threshold, each electrode (0,1,2,3) will b e programmed as the cathode (negative) in a bipolar configuration in a systematic fashion. As part of the programming, impedance checks should be completed. Upon completion of programming, data will be collected via a pr intout or NPU."
27,page_27,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 27 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  Subjects will complete the following questionnaires: xICIQ-OABqol  The subject is exited from the study after the 12-week follow-u p visit is complete. Programming parameters after the subject has completed the study are at the Investigator‚Äôs discretion. Unscheduled Visit If an unscheduled visit is neede d for any device-related reason , the subject‚Äôs sensory threshold amplitude will be confirmed by f ollowing this protocol: start a t 0.05 V and increase voltage in 0.05V increments until the subject repo rts sensation. Prior to the c ompletion of the study , the amplitude at each electrode configuration that elicits a sensory response mu st be determined in seated positions. To determine sensory threshold, each electrode (0,1 ,2,3) will be programmed as the cathode (negative) in a bipolar configuration in a systematic f ashion. Following determination of sensory threshold amplitude, amplitu de will be programmed based on the assigned randomization using the sensory threshold in a seated position. Subjects will be allowed to adjust amplitude +/- 0.05 V durin g the trial. As part of the p rogramming, impedanc e checks should be completed. Upon completion of p rogramming, data will be collec ted via a programming printout or NPU. All efforts should be made to ma intain subject in the randomize d arm. If the subject must be changed from their randomized arm, subjec ts should be encouraged to com plete a 3-day voiding diary prior to the unscheduled visit. In addition to programming activities, any reportable adverse e vents and device deficiencies will be collected. Surgical Revision If a surgical revision is required after the full system implan t, the subject will be exited from the study."
28,page_28,
29,page_29,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 29 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  Table 9-1: Study Procedures Enrollment / Baseline Tined Lead or Test Stimulation Lead Implant Therapy Evaluation Tined Lead (if applicable)/ Neurostimulato r Device Implant 1-Week Follow-Up Visit (+/- 3 days) 6-Week Follow-Up Visit (+/- 7 days) 12-Week Follow-Up Visit (+/- 7 days) Unscheduled Visit Informed Consent X* Randomization Procedures X*** Relevant Medical History X ICIQ-OABqol Questionnaire X X Pregnancy Assessment X Assessment of Sensory Threshold X X X X X X PGI-I Questionnaire X X 3-Day Voiding Diary X** X** X X X**** Device Interrogation/ Programming Data X X X X X X X Assessment of Reportable Adverse Events and Device Deficiencies X X X X X X X X * Must occur prior to any st udy specific activities **50% improvement in UUI or UF vo iding symptoms, or return to n ormal voiding of < 8 voids per day for UF subjects, required fo r neurostimulator implant ***Randomization must occur after study qualification; however, may be prior to or after neurostimulator device implant ****If the subject must be change d from their randomized arm, s ubjects should be encouraged to complete a 3-day voiding diary prior to the unscheduled visit. Note: Programming settings of 14 hz, 210 pw and continuous stim ulation are required following the neurostimulator device impla nt for the duration of the study"
30,page_30,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 30 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH   6XEMHFW6FUHHQLQJ  Subjects may be recruited throug h the investigator‚Äôs practice a nd referring physicians. Potential subjects may be identi fied through chart reviews or a s new or existing patients attend clinic visits as appropriate. If subjects are recruited from outside the investigator‚Äôs practice, sites are to ensure that appropriate release for access to the subject‚Äôs rec ords (paper and/or electronic) is obtained. Any subject recruitment materials disseminated to subjects (adv ertisements, handouts, posters, social media) must be approved by the IRB/EC prior to use. All subjects must be consented i n accordance wit h the protocol prior to any study-specific procedures. Recruited subjects will be screene d by the Principal Investigat or or authorized site personnel by reviewing the study‚Äôs inclusion and exclusion criteria. A screening log should be completed by the site to maintain a c umulative log of all screened subjects with reason for screening failure. The Investigator will maintain a listing of all subjects enroll ed in the study.  6XEMHFW&RQVHQW The informed consent process will be performed in accordance wi th the ethical principles that have their origin in the Declaration of Helsinki, 21CFR¬ß50 Protectio n of Human Subjects (US only), SOR/98- 282 (Canada only) and in accorda nce with local regulatory requi rements. No vulnerable patients will be allowed to be consented to par ticipate in the study. Data will be collected and treated in accordance with applicable Data Privacy Legislation. With regard to the EU this includes Directive 95/46/EC and subsequent legislation. Prior to entering the study, the Principal Investigator or qual ified designee will explain to each subject the purpose and nature of the st udy, procedures, expected study duration, available alternative therapies, and the benefits and risks involved with study parti cipation and the potential treatment. The person obtaining consent will av oid any coercion or undue impro per influence on, or inducement of, the subject to participate and the ICF will not waive, or appear to waive, any legal rights. Subjects will be given a copy of the IRB/EC appr oved ICF and will have ample tim e to review the document and to ask questions and will be informed of their right to withdraw from the study at any time without prejudice; ICFs will be provided in a langu age understandable to the subje ct. After this explanation and before any study-specific procedures have been performed, the subject will voluntarily sign and personally date the"
31,page_31,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 31 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  ICF. Prior to participation in t he study, the subject will rec eive a copy of the signed and dated written informed consent and any other written information provided to the subject. The Principal Investigator or qua lified (delegated) designee wi ll document the informed consent process, including the date of consent and name of the person c onducting the consent process in the subject‚Äôs medical record. A cop y of the signed ICF will also b e placed in the subjec t‚Äôs medical record. Throughout study participation, any significant new information will be provided to the subject as outlined in the informed consent form. As appropriate, the ICF may be revised based on new information that becomes available. 5DQGRPL]DWLRQDQG7UHDWPHQW$VVLJQPHQW Once the subject meets all elig ibility criteria for the study, and has a successful the rapy evaluation, site personnel may proceed with the n eurostimulator device implant a nd randomization procedures. If a subject does not meet all eligib ility criteria, subjects should be exited and not proceed to the neurostimulator device implant and randomization procedures. At the time of the device implant, site personnel will obtain r andomization for one of the following therapy amplitudes: sensory thr eshold, 50% of sensory threshold or 80% of sensory threshold. Randomization will be assigned in a 1:1:1 ratio, and stratified by site. Site personnel will obtain the subject‚Äôs randomization sequence on the Randomization eCRF whic h will be generated from the database. The investigator and research staff at the study site will be i nstructed to keep the subject blinded to their randomization; however, s ubjects may or may not feel stim ulation. The outcome measures in this study are based on the subject‚Äôs own assessment. Therefore, kee ping the subject blinded to their randomization reduces bias in the outcome measurement reporting . During the study, subjects will be encouraged to remain in the randomized treatment arm; however, a subject may request to be re-programmed with a different amplit ude setting. If this occurs, a protocol deviation will be required and subjects should continue in the study and complete the remaining follow- up visits. "
32,page_32,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 32 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH   $VVHVVPHQWRI(IILFDF\ Subject assessments will be perf ormed by appropriately trained, qualified and delegated site personnel according to the usual practices of the site. Urinary Voiding Diary Symptoms related to OAB will be evaluated using paper voiding d iaries. Subjects will be trained to complete the urinary voiding diaries for 3-days as part of the baseline and therapy evaluation procedures. The voiding diaries will be completed at baseline, therapy evaluation and prior to the 6 and 12-week follow-up visits. Every effort should be made to remind subjects of the importance of real-time diary completion. Voiding diary data will be used t o verify study inclusion crite ria for UUI episodes at baseline. Diaries will also be used for comparison of e fficacy from 12-week follow-up visit to baseline for the primary study endpoint of UUI Assessments for Quality of Life Measures Subjects will complete the study questionnaires confidentially on paper forms without site personnel consultation and these data will be entered to OC/RDC by site p ersonnel. Questionnaires should be completed prior to the follow-up visit when data is collected. Site personnel are encouraged to review forms for completeness. ICIQ-OABqol Questionnaire The ICIQ-OABqol is a robust, pat ient-completed questionnaire fo r evaluating quality of life (QoL) in patients with overactive bladder, for use in research and clini cal practice.9 The questionnaire used in the current study includes 26 questio ns which are 4-week recall for symptom assessment."
33,page_33,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 33 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH   $VVHVVPHQWRI6DIHW\ 9.8.1 Reportable Adverse Eve nts and Device Deficiencies All reportable adverse events and device deficiencies will be c ollected throughout the study once the informed consent form is signed.  5HFRUGLQJ'DWD This study will be conducted using a remote data capture system . The Oracle Clinical Remote Data Capture (RDC) system which allows the study centers to enter st udy data into the sp onsor‚Äôs database over a secure internet connection, will be used to capture stud y required Case Report Form (CRF) information. Data reported on v oiding diaries and subject ques tionnaires will be entered to the database by site personnel. Subj ects will complete the study q uestionnaires confidentially on paper forms without site personnel cons ultation and these data will b e entered to OC/RDC by site personnel. Electronic CRFs (eCRFs) will be provided by the sponsor; requir ed data will be taken from source documents and directly entered into the study database via the CRFs by the site personnel, in accordance with applicable regulations. Device interrogation (programming ) data may be transmitted usin g either NPU or by manual data entry on a programming CRF. Subject voiding diaries and ques tionnaires are to be completed only by the subject. Representatives from the research site may not make entries to the diaries or q uestionnaires except for administrative clarification on source documentation. The Principal Investigator, Sub- Investigator, or an individual delegated by the Principal Investigator on the Delegation of Authority and Signature Form, are responsible for documenting and entering data for the study on the eCRF s. The Principal Investigator or Sub-Inve stigator is required to approve all data on CRFs via electronic signature. 'HYLDWLRQ+DQGOLQJ Protocol deviations are digressi ons from the written protocol d efined as an event where the clinical investigator or site personnel did not conduct protocol-require d procedures according to the study protocol. Protocol deviations a re to be preapproved by Medtron ic study personnel and the IRB/EC (as required) unless the deviation is necessary to protect the heal th, safety, or welfare of a subject in an emergency situation. The invest igator or delegated site person nel should contact the designated Medtronic study personnel to dis cuss the impact of the potentia l deviation; prior approval of deviations should be documented. Prior approval is generally not required if the deviation is due to an emergency circumstance or an unforeseen cir cumstance that is beyond the i nvestigator‚Äôs control; however, these deviations should be reported to Medtronic and the IRB/EC (as r equired) after site personnel become"
34,page_34,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 34 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  aware of the deviation. Site pe rsonnel should work with subjec ts to ensure subject follow-up visits are scheduled within the visit window; however, any visits complete d outside of the visit window will require a protocol deviation to be reported. All protocol devi ations must be reported on the Protocol Deviation eCRF after the site‚Äôs awareness of the deviation. The sponsor may choose to termin ate the study at a site for fai lure to follow the written protocol and investigator agreement. If this occurs, the Investigator, IRB/ EC and governing regulatory authority (if applicable) will be notified in writing of the reasons for the termination. 6XEMHFW:LWKGUDZDORU'LVFRQWLQXDWLRQ Subjects are free to voluntarily withdraw from the study at any time and for any reason. All implanted subjects will be followed until the 12-week follow-up visit, un less withdrawn from the study. Withdrawn or exited subjects will be follo wed under normal medical practi ce. Examples of reasons for study di scontinuation include, but are not limited to, those listed below: xIf the subject does not meet eligibility criteria of at least 3 UUI episodes demonstrated on a 3- day baseline urinary voiding diary xSubject death xSubject lost to follow-up xSubject voluntarily withdraws from the study xSubject becomes pregnant xInvestigator terminates the subj ect‚Äôs participation in the stud y due to lack of compliance, violation of/change in eligibility criteria xAny clinical laboratory abnorma lity, current illness, or other medical condition or situation occurs such that continued study participation would not be in the best interest of the subject. xSubject is not a candidate for InterStim Therapy xNormal study completion Prior to deeming a subject lost t o follow-up, telephone calls m ust be documented in the subject‚Äôs medical record. If a minimum of three attempts to contact the s ubject have failed (e.g. phone and mailed letter), and no response is received, the site should ex it the subject and complete the Study Exit eCRF. When a subject is withdrawn fro m the study, the Study Exit eCRF is to be completed and should include detailed notes as to why the subject was withdrawn from the stu dy (e.g., discomfort, lack of efficacy, diary too burdensome). Withdraw n subjects will not be replaced ."
35,page_35,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 35 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  Once a subject completes partic ipation in the study, follow-up will continue in accord ance with the site‚Äôs standard of care. No study spec ific medical care will be provi ded for a subject after discontinuation from the study, unless outlined in the Clinical Trial Agreement and Informed Consent Form. 5LVNVDQG%HQHILWV 3RWHQWLDO5LVNV The risks outlined below are the same risks found in commercial InterStim II System use; however, based on the amplitude settings, subjects may experience less t han desired improvements in OAB symptoms. No additional study specific risks are present. 5LVNV2XWOLQHGLQWKH,QVWUXFWLRQVIRU8VH ,)8  Refer to the appropriate Instructions for Use (IFU) for the Int erStim System components for updated list on contraindications, precaution s, warnings, adverse events, di rections for use and other product specific details. In addition to the risks normally associated with surgery, impl antation, or use of a neurostimulation system includes, but is not limited to, the following risks. Ce rtain adverse events may necessitate surgical intervention. Õªƒö«Äƒû∆å∆êƒûƒê≈öƒÇ≈∂≈êƒû≈ù≈∂«Ä≈Ω≈ùƒö≈ù≈∂≈êƒ®∆µ≈∂ƒê∆ö≈ù≈Ω≈∂Õæƒè≈Ω«Åƒû≈ØƒÇ≈∂ƒöÕ¨≈Ω∆å bladder) Õª≈Ø≈Øƒû∆å≈ê≈ùƒê≈Ω∆å≈ù≈µ≈µ∆µ≈∂ƒû∆ê«á∆ê∆öƒû≈µ∆åƒû∆ê∆â≈Ω≈∂∆êƒû∆ö≈Ω∆ö≈öƒû≈ù≈µ∆â≈ØƒÇ≈∂∆öƒûƒö≈µƒÇ∆öƒû∆å≈ùƒÇ≈Ø∆ê ∆ö≈öƒÇ∆öƒê≈Ω∆µ≈Øƒö∆åƒû∆ê∆µ≈Ø∆ö≈ù≈∂ device rejections Õª≈öƒÇ≈∂≈êƒû≈ù≈∂∆êƒû≈∂∆êƒÇ∆ö≈ù≈Ω≈∂≈Ωƒ®∆ê∆ö≈ù≈µ∆µ≈ØƒÇ∆ö≈ù≈Ω≈∂«Å≈ö≈ùƒê≈ö≈öƒÇ∆êƒèƒûƒû≈∂ƒöƒû∆êƒê∆å≈ùƒèƒûƒöƒÇ ∆ê∆µ≈∂ƒê≈Ω≈µƒ®≈Ω∆å∆öƒÇƒè≈ØƒûÕæ≈©≈Ω≈Ø∆ö≈ù≈∂≈ê or shocking) by some patients Õª/≈∂ƒ®ƒûƒê∆ö≈ù≈Ω≈∂ ÕªEƒû«Å∆âƒÇ≈ù≈∂ ÕªPain at neurostimulator and or lead site Õª^ƒû∆å≈Ω≈µƒÇÕï≈öƒû≈µ≈Ω∆å∆å≈öƒÇ≈êƒûÕï≈öƒû≈µƒÇ∆ö≈Ω≈µƒÇ Õª^∆µ∆ê∆âƒûƒê∆öƒûƒö≈ØƒûƒÇƒö≈Ω∆å≈∂ƒû∆µ∆å≈Ω∆ê∆ö≈ù≈µ∆µ≈ØƒÇ∆ö≈Ω∆å≈µ≈ù≈ê∆åƒÇ∆ö≈ù≈Ω≈∂≈Ω∆åƒû∆å≈Ω∆ê≈ù≈Ω≈∂ Õª^∆µ∆ê∆âƒûƒê∆öƒûƒö≈∂ƒû∆å«Äƒû≈ù≈∂≈©∆µ∆å«á Õª^∆µ∆ê∆âƒûƒê∆öƒûƒö∆öƒûƒê≈ö≈∂≈ùƒêƒÇ≈Øƒöƒû«Ä≈ùƒêƒû∆â∆å≈Ωƒè≈Øƒû≈µ Õªd∆åƒÇ≈∂∆ê≈ùƒû≈∂∆öƒû≈Øƒûƒê∆ö∆å≈ùƒê∆ê≈ö≈Ωƒê≈¨ The safety of SNM has not been established for pregnant women, for an unborn fetus, or during childbirth. This precaution is provided in the InterStim Therap y commercial labeling and should be adopted in this study; thus, no one who is pregnant or planning to become pregnant will be enrolled."
36,page_36,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 36 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  If a subject learns or suspects t hat she is pregnant, the inves tigator will instruct her to turn her neurostimulator OFF and to visit the study site as soon as poss ible; however, this will not be considered a reportable AE. 3RWHQWLDO%HQHILWV Subjects may not receive any dir ect medical benefit from partic ipation in this study but subjects will receive additional medical overs ight of treatment. Participati on in this study may not provide greater benefit than if the subject was receiving InterStim Therapy out side of the study, as required study programming is within approved programming specifications. Inf ormation from this study might help researchers further understand InterStim Therapy related to unc omfortable stimulation. The benefit to subjects participating in this s tudy, and to future patients, r esides in the knowledge gained from this study. 5LVN%HQHILW5DWLRQDOH Participation in this study will not expose the subject to grea ter risks than if he/she were receiving InterStim Therapy outside of the study. There might be other di scomforts and risks related to InterStim Therapy and/or this study that are not foreseen at this time. In addition, based on the amplitude settings, subjects may experience less than desired improvement s in OAB symptoms. The risks associated with InterS tim II System are minimized in this study by selecting only qualified Investigators experien ced in InterStim Therapy, selecting an ap propriate patient population via inclusion/exclusion screening, a nd monitoring subject progress and events reported for this study. The review and minimization of the potential risks to the patient a nd the potential benefits to the patient support the conduct of this study. $GYHUVH(YHQWVDQG'HYLFH'HILFLHQFLHV 'HILQLWLRQV&ODVVLILFDWLRQV Any adverse event meeting the def inition of: serious, device re lated, therapy related and/or procedure related as well as all device deficiencies will be considered r eportable for this study. The term ‚Äúinvestigational device‚Äù is part of ISO14155 definitions. The term ‚Äúinvestigational device‚Äù refers to any device used in the study including market released devices. Ad verse events and device deficiencies are defined as follows:"
37,page_37,
38,page_38,
39,page_39,
40,page_40,
41,page_41,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 41 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  if necessary request clarification and/or additional informatio n from the Investigator. If Medtronic disagrees with the Investigator‚Äô s assessment of the adverse eve nt relationship to device, therapy and/or procedure, Medtronic study perso nnel will document the disagree ment and report or ensure reporting of both opinions to IRB/EC as necessary. All reported adverse events and device deficiencies will be reviewed by a Medtronic Medical Ad visor to ensure consistent re porting 'HYLFH'HILFLHQFLHV A device deficiency (DD) is an i nadequacy of a medical device w ith respect to its identity, quality, durability, reliability, safety or performance. Device deficien cies include malfunctions, misuse or use errors, and inadequate labeling. All device deficiencies must b e documented and submitted to Medtronic on the Device Deficiency eCRF. In addition, the Inves tigator must also determine and document on the eCRF device deficiencies that did not lead to a dverse event but could have led to a serious adverse device effect: –¨ if either suitable action had not been taken, –¨ if intervention had not been made, or –¨ if circumstances had been less fortunate 'HDWKV All subject deaths must be repor ted to Medtronic and the IRB/EC as soon as possible, but no more than 5 working days after learning of a subject‚Äôs death, regardless of whether or not the death is related to the device system or therapy. If limited information is known, the Adverse Event eCRF must be completed with available informat ion as soon as possible. As in formation becomes available, the eCRF will be updated. If the death occ urs at a location remote from the study site, it is the study site‚Äôs responsibility to make every attempt to retrieve all pertinent information related to the subject‚Äôs death and submit the investigator‚Äôs de ath summary of the known events surrounding the death to Medtronic or its designee. The Investigator should also attempt to deter mine, as conclusively as possible, whether such deaths are related to the d evice system, therapy, and/or p rocedure. If the death is evaluated as device, therapy and/or procedure related and unanticipated, the event will be reported as a USADE by Medtronic or its designee to the appropriate regulatory agencie s. In addition, the principal investigator should follow commercial medical device reporting requirements. The principal investigator should provide as much of the following supporting documentation as po ssible for deaths:"
42,page_42,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 42 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  xDeath certificate xDeath summary/hospital records, if allowed by state/local law xAutopsy report, if allowed by state/local law All device system components that were being used at the time o f the death should be returned to Medtronic for analysis, if applic able. Any subject death will b e reported on the Adverse Event and Study Exit CRFs. 'DWD5HYLHZ&RPPLWWHHV This study will not use a Clinic al Events Committee or Data Mon itoring Committee. Instead, all reported adverse events and device defici encies will be reviewed by a Me dtronic Medical Advisor to ensure consistent reporting as de fined in Section 11.2. 6WDWLVWLFDO'HVLJQDQG0HWKRGV *HQHUDO6WDWLVWLFDO&RQVLGHUDWLRQV This study is a three-arm parall el design to explore effectiven ess, and quality of life under three amplitude settings. For the prim ary objective, the primary anal ysis will be performed in the complete case (CC) population, or the pop ulation of subjects who have da ta available at baseline and follow-up based on their randomization. Details of the primary and supporting analyses are outlined in the sections below. Continuous measures will be repo rted as N, means, medians, stan dard deviations, minimums and maximums. All summaries will be p rovided by group. Categorical measures will be reported in frequency distributions. Data analysis will be performed by Medtronic-employed statistic ians or designees. A validated statistical software package (e.g., SAS vers ion 9.2 or higher) will be used to analyze the study results. The Statistical Analysis Plan (SAP) will be developed prior to data analysis and will include a comprehensive description of the statistical methods and report s to be included in the final study report. Any change to the data a nalysis methods described in th e CIP will require an amendment only if it changes a principal feature o f the CIP. Any other change to the data analysis methods described in the CIP, and the justification for making the change, will be descr ibed in the clinical study report."
43,page_43,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 43 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  6WXG\6DPSOH6L]H-XVWLILFDWLRQ This study will explore the effect of three different amplitude settings (50% of sensory threshold, 80% of sensory threshold, and sensory threshold) on UUI episodes per d ay. Change of average UUI per day at 12-week follow-up will be assessed under each amplitude setting . This study requires approximately 42 implanted and randomized subjects with 12-week follow-up data t o be analyzed for the primary objective. Assuming 10% attritio n after full system implant and 80% therapy evaluation success rate, approximately 48 subjects will be implanted and randomized in 3 arms. However, these numbers may be exceeded to ensure that a m inimum of 42 subjects complete th e study. The objectives are descriptive in nature. Confidence interval s will be calculated to describe the precision of the treatment effec t in each arm. Precision is def ined as one-half of the confidence interval (also known as the distance from the confidence limits to the m ean). Sample size calculations were completed using the PASS 11 Confidence Intervals for One Mean m odule. From the randomized portion of the InSite study13, a mean reduction of 2.1¬±1.8 UUI episodes per day was observed at 3 months in SNM subjects; and from the all impl anted cohort of InSite, a mean reduction of 2.3¬±2.7 UUI episodes per day was observed at 3 mon ths in SNM subjects. Based on this, we are assuming mean redu ctions between 1.8 a nd 2.3 will be observ ed in the study, along with standard deviations ranging from 2.2 to 2.7. Based on a confidence interval con structed with a t-statistic, a two-sided type-I error rate of 0.05, and using the largest standard devia tion assumed (2.7), a sample si ze of 14 subjects per arm will have a precision of 1.56 (Table 13-1). This precision is less than our lowest assumed treatm ent effect (1.8 UUI), so that it is expected that the lower 95% CI will be greater th an 0 for all treatment arms, even in the scenario when the largest assume d standard deviation is applied . Table 13-1. Standard deviations and precision Standard deviation Precision 2.2 1.27 2.3 1.33 2.4 1.39 2.5 1.44 2.6 1.5 2.7 1.56"
44,page_44,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 44 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  'HVFULSWLRQRIGHPRJUDSKLFDQGEDVHOLQHYDULDEOHV Summary statistics will be provided, by group, for baseline and demographic variables for subjects who are enrolled and randomized. &HQWHU3RROLQJ Data from all study centers will be pooled for the analysis. Th ere are no planned statistical methods to test for treatment differences a mong centers. The study will be conducted at approximately 20 centers in the United States, Canada and Europe. 0LVVLQJ'DWD Missing data imputations will not be performed. ,QWHULP$QDO\VLV No formal interim analysis is pl anned for this study. Interim descriptive summaries may be performed; however, if provided, the study t eam, investigators and site pe rsonnel will be blinded to this information. No study decisions will be made from descriptive s ummaries; therefore, no sample size adjustment is needed. 5HSRUWV A final report will be generated for this study. Periodic prog ress reports may also be generated for the study. 6WXG\6XFFHVV As the study objective is to characterize the efficacy and QoL of 3 different amplitude settings, there is no pass/fail criteria propose d to define study success. 6XEJURXS$QDO\VHV Subgroup analyses will be detailed in the SAP, if any will be c onducted.  3DWLHQW3RSXODWLRQV The full analysis patient set (FA S) includes all subjects who s igned the study-specific ICF and enrolled in the study. The complete case (CC) patient set will consist of the subject set who have data ava ilable at baseline and follow-up."
45,page_45,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 45 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  3ULPDU\2EMHFWLYH 3ULPDU\REMHFWLYH To explore the effect of three different amplitude settings (50 % of sensory threshold, 80% of sensory threshold, and sensory threshold) on urinary urge incontinence (UUI) episodes per day. Descriptive statistics for chang e in UUI from ba seline to 12 we eks will be provided in each randomized group. Negative values for a change from baseline represent an improve ment in UUI episodes and positive values represent an incr ease in UUI episodes. ([SHULPHQWDOGHVLJQ Subjects‚Äô number of UUI episodes will be reported in the voidin g diary. Data will be collected daily in the 3 days prior to each visit for a ll subjects and the value repor ted at each visit will be calculated as the daily average of the available di ary days at that visit. All av ailable data will be used for analysis, regardless of whether 1 day is av ailable or 3 days are availabl e. The change in scores from Baseline to 12 weeks will be calculated for each subject and the average ch ange across all subjects in each group will be reported. (QGSRLQWVXFFHVVGHILQLWLRQ This objective is to explore and characterize the reduction in number of UUI episodes under each amplitude setting from baseline. There are no pass/fail criter ia proposed to define this endpoint success. $QDO\VLVPHWKRGV Descriptive statistics including mean, standard deviation, 95% confidence intervals, median, minimum and maximum will be provided. $QDO\VLVSRSXODWLRQVDQGVHQVLWLYLW\DQDO\VHV The analysis population for this objective will be on the CC po pulation, as described in Section 13.1.9. In addition to the primary analys is, an as-treated (AT) sensiti vity analysis will be completed to assess the robustness of results. The AT a nalysis will include the populat ion of subjects who have data available at baseline and 12 weeks, but will analyze subjects according to t he treatment they receive. In addition to the summaries described above, responder rate an alyses will be conducted to further describe the treatment effect of each randomization group. Resp onder rates will be described as the percent of patients who achieve therapeutic success, defined as ƒ± 50% reduction in average UUI episodes/day from baseline to 12 weeks, divided by the number o f subjects included in the analysis."
46,page_46,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 46 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  Responder rate analyses will be co mpleted based on the CC and A T analyses described above. 6HFRQGDU\2EMHFWLYH 6HFRQGDU\REMHFWLYH To explore the effect of three different amplitude settings (50 % of sensory threshold, 80% of sensory threshold, and sensory threshold) on quality of life with the I CIQ-OABqol Questionnaire. Descriptive statistics for the change in all domains of this qu estionnaire from baseline to 12 weeks will be provided in each randomized group. ([SHULPHQWDOGHVLJQ The change in each subscale score from Baseline to 12 weeks wil l be calculated for each subject and the average change across all subjec ts in each group will be report ed. (QGSRLQWVXFFHVVGHILQLWLRQ This objective is to explore and characterize the QoL under eac h amplitude setting from baseline to 12 weeks. There are no pass/fail cr iteria proposed to define this endpoint success. $QDO\VLVPHWKRGV Descriptive statistics including mean, standard deviation, 95% confidence intervals, median, minimum and maximum will be provided. $QDO\VLVSRSXODWLRQVDQGVHQVLWLYLW\DQDO\VHV The analysis population for th is objective will be on the CC po pulation, as described in Section 13.1.9. In addition to the primary analys is of the secondary objective, an as-treated (AT) sensitivity analysis will be completed to assess the robustn ess of results. The AT analys is will include the po pulation of subjects who have data available at base line and 12 weeks, but will anal yze subjects according to the treatment they receive.  $GGLWLRQDO 0HDVXUHV Additional measures have been added to provide relevant informa tion on parameters of interest in SNM therapy under different amplitude settings and to provide addit ional information."
47,page_47,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 47 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  Additional measures to summarize are: xIncidence of device-related, procedure-related and/or therapy-r elated adverse events   Reportable device-related, procedure-related and/or therapy-rel ated adverse events will be summarized for subjects who are implanted and randomized under each amplitude setting. Device- deficiencies will be summarized in the similar fashion. In addi tion, serious adverse events will be summarized. (WKLFV 6WDWHPHQW V RI&RPSOLDQFH The study will be conducted in accordance with this protocol, t he ethical principles that have their origin in the Declaration of Helsinki have been implemented in this cl inical study by means of the informed consent process, EC/IRB approval, study training, and risk bene fit assessment. In addi tion, all applicable laws and regulatory requirements of the country/ies in which th e study is conducted will be followed and in accordance with GCP."
48,page_48,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 48 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  xIn the US, the study will be con ducted in accordance with 21 CF R¬ß11 Electronic Records, Electronic Signatures, 21CFR¬ß50 Protection of Human Subjects, 2 1CFR¬ß56 IRB, and 21CFR¬ß803 Medical Device Reporti ng. Financial disclosures wil l be collected; however, this study is not considered a ‚Äúcove red study‚Äù under 21 CFR¬ß54 Finan cial Disclosure by Clinical Investigators. xIn Europe, the study will be conducted in accordance with regio nal or national regulations, as appropriate. xIn Canada, the study will be conducted in accordance with Canad a Medical Devices Regulations, 1998 (SOR/98-282), and the Guidance document for Mandatory Prob lem Reporting. Any additional requirements imposed by the IRB/EC or governing regulatory authority shall be followed, if appropriate. Medtronic will distribute the appr oved version of the CIP and a ll other materials requ ired to conduct the study. Prior to site activation, Medtronic will provide study training relevant and pertinent to the involvement of personnel conduct ing study activities and invest igator responsibilities. Medtronic will not activate any site until the required approval/favorable opi nion from the Institutional Review Board (IRB)/Ethics Committee (EC) or no tification/approval from a reg ulatory authority have been obtained, if appropriate. Site personnel must inform Medtronic of any change in status of the IRB/EC a pproval once the site has started enrollment. 3ULQFLSDO,QYHVWLJDWRU2YHUVLJKW The Principal Investigator will provide adequate oversight to e nsure the study is conducted in accordance with all protocol requirements, all applicable regul atory requirements and any applicable institutional requirements rela ted to the conduct of clinical r esearch. The Princip al Investigator will ensure no study-related activities occur prior to regulatory an d IRB/EC approval. Any actions taken by the IRB/EC with respect to the i nvestigation will be forwarded to Medtronic as soon as possible. The Principal Investigator is respon sible for submitting all requir ed reports to the sponsor and/or IRB/EC. Regulatory reporting of AEs/DDs w ill be completed according to local regulatory requirements. It is the responsibility of the Investigator to abide by any additional A E/DD reporting requir ements stipulated by the IRB/EC responsible for overs ight of the study. Investigator s should report seri ous adverse events, device-, procedure- and therapy-re lated adverse events and devi ce deficiencies to Medtronic after the Investigator learns of the event in accordance with Table 14-1."
49,page_49,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 49 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  In addition, Principal Investigator, or designated personnel wi ll provide Medtronic with the following minimum information related to s erious adverse events, device-, procedure- and/or therapy-related adverse events and device deficiencies: xDate of adverse event or device deficiency xTreatment provided xResolution date xAssessment of seriousness xRelationship to the device, therapy and/or procedure Failure to perform the investigat or obligations or to complete corrective and preventive actions identified during monitoring or auditing activities may result in Principal Investigator or site personnel disqualification, and/or lead to suspension or termination of t he study at the site. Table 14-1 includes minimum reporting requirements for investig ators participating in studies in Europe, the US and Canada. Medtronic st udy personnel will immediately report Adverse Eve nts and Device Deficiencies, related to a CE ma rked or FDA approved device use d during the study, to Medtronic‚Äôs Compliant Handling Unit who will ensure prompt review and appro priate reporting. The Therapeutic Products Directorate is a divisi on of Heath Canada, and is resp onsible for regulating therapeutic products including Food, Drugs, Medical Devices, Natural Health Products, Cells, Ti ssues and Organs and Cosmetics. Table 14-1 includes minimum reporting requirements in Canada. Table 14-1 5HSRUWLQJ5HTXLUHPHQWV Serious Adverse Events (SAEs) Investigator submit to: Medtronic Europe: Immediately after the investigator first learns of the event or of new information in relation wi th an already re ported event All other geographies: Report to the sponsor, without unjustified delay, all serious adverse events IRB/EC All geographies: Reporting timeframe as per local EC/IRB per local requirement Sponsor submit to: EC/IRB All geographies: Reporting timeframe as per local EC/IRB per local requirement Regulatory Authorities All geographies: Reporting timeframe as per local requirement Serious Adverse Device Effects ( SADEs), Unantici pated Serious D evice Effects (USADEs) and Unanticipated Adverse De vice Effects (UADEs)"
50,page_50,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 50 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  Investigator submit to: Medtronic US: As soon as possible to meet regulatory reporting requirements, but no later than 10 days after the date you become aware Europe: Immediately after the investiga tor first learns of the event o r of new information in relation wi th an already re ported event All other geographies: Submit as soon as possible af ter the Investigator first learns of the event, and per local requirements IRB/EC Reporting timeframe as p er local EC/IRB requirement Sponsor submit to: EC/IRB All geographies: Reporting timeframe as per local EC/IRB per local requirement Regulatory Authorities Canada (Medtronic of Canada Regul atory Compliance) to submit to Health Canada: As soon as possible to meet regulatory reporting requirements within 10 days after the date Medtronic becomes aware All other geographies: Reporting timeframe as per local requirement All Other Adverse Events Investigator submit to: Medtronic All geographies: Submit in a timely manner after the Investigator first learns of the event IRB/EC All geographies: Reporting timeframe as per local EC/IRB requirement Deaths Investigator submit to: Medtronic All geographies: All subject deaths must be r eported to Medtronic and the IRB/EC as soon as possible, but n o more than 5 working days of learning of a subject‚Äôs death, regardless of whether or not the death is re lated to the device system or therapy IRB/EC All geographies: All subject deaths must be r eported to Medtronic and the IRB/EC as soon as possible, but n o more than 5 working days of learning of a subject‚Äôs death, regardless of whether or not the death is re lated to the device system or therapy USADE, SADE, DD (Canada only) (referred to here as ‚Äúincidents‚Äù) occurring outside Canada requ iring corrective action or imposed by local regulatory authorities Sponsor submit to: Regulatory Authorities Canada (Medtronic of Canada Regulatory Compliance) to submit re port to Health Canada: When Medtronic has indicated to a regulatory authority of the c ountry in which the incident occurred, int ention to take corrective actio n, or if the regulatory authority has required Medtronic to take corrective action. In this case, the incident must be reported to the Health Canada a s soon as possible after either Medtronic has reported to the local regul atory authority or a corrective action has been imposed by the local regulatory"
51,page_51,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 51 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  authority. Device Deficiencies that has resulted in an SAE (Canada only) Sponsor submit to: Regulatory Authorities Canada (Medtronic of Canada Regulatory Compliance) to submit re port to Health Canada: As soon as possible to meet regulatory reporting requirements within 10 days after the date Medtronic becomes aware Device Deficiencies (DD) with SADE potentials Investigator submit to: Medtronic US & Europe: Immediately after the investigator first learns of the deficiency or of new information in relation with an already re ported deficiency All geographies: Report to the sponsor, without unjustified delay, all device deficiencies that could have led to a serious adverse device ef fect IRB/EC All geographies: Reporting timeframe as per local EC requirement Sponsor submit to: EC/IRB All geographies: Reporting timeframe as per local EC/IRB requirement Regulatory Authorities Canada (Medtronic of Canada Regulatory Compliance) submits to H ealth Canada: As soon as possible to meet regulatory reporting requirements within 30 days after the date Medtronic becomes aware All other geographies: Reporting timeframe as per local requirement All other Device Deficiencies Investigator submit to: Medtronic All geographies: Submit in a timely manner after the investigator first learns of the deficiency IRB/EC All geographies: Reporting timeframe as per local EC requirement Withdrawal of IRB Approval Investigator submit to: Medtronic All geographies: Report a withdrawal of the reviewing EC/IRB approval within 5 days of investigator notification Protocol Deviations for Emergency Reasons Investigator submit to: Medtronic US: Submit to Medtronic and IRB within 5 working days of the occur rence of an emergency deviation (made to protect the life or physical well-being of a subject) Canada: Per institutional guidelines, report protocol deviations to Medtronic EC/IRB US: Submit to Medtronic and IRB within 5 working days of the occurrence of an emergency deviation (made to protect the life or physical well-being of a subject) Canada: Per institutional guidelines, re port protocol deviations to the"
52,page_52,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 52 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  reviewing IRB Prior Notification of Protocol Deviations Medtronic All geographies: Except in the occurrence of an em ergency deviation, the Investi gator must obtain prior approval from Medtro nic of protocol deviations. Pr ior approval from the IRB may also be required according to local requiremen ts. EC/IRB All geographies: Except in the occurrence of an em ergency deviation, the Investi gator must obtain prior approval from Medtro nic of protocol deviations. Pr ior approval from the IRB may also be required according to local requiremen ts. Failure to Obtain Informed Consent Investigator submit to: Medtronic US and Europe: The Investigator must notify Medtronic within 5 working days upon awareness Canada: The Investigator must notify Medtronic within 5 working days after procedure EC/IRB US and Europe: The Investigator must notify the EC/IRB within 5 working days after upon awareness Canada: The Investigator must notify the EC/IRB within 5 working days after SURFHGXUH Final Report Medtronic US and Europe: Study reports must be submitted within 6 months after termination or completion of the investigation or as required b y applicable regulation Canada: Study reports must be submitted within 3 months after termination or completion of the investigation or as required b y applicable regulation EC/IRB US and Europe: Study reports must be submitted within 6 months after termination or completion of the investigation or as required b y applicable regulation Canada: Study reports must be submitted within 3 months after termination or completion of the investigation or as required b y applicable regulation"
53,page_53,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 53 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  6WXG\$GPLQLVWUDWLRQ  6SRQVRU This study is sponsored by: Medtronic, Inc. 7000 Central Avenue NE Minneapolis, MN 55432 USA A list of sponsor‚Äôs study staff wi ll be provided as a separate document to site personnel. Sponsor will maintain an updated list of contact information. 6LWH6HOHFWLRQ The role of the principal investigator is to implement and mana ge the day-to-day cond uct of the study as well as ensure data integrity and the rights, safety and well-b eing of the patients inv olved in the study. Site selection criteria will be documented and utilized to ensu re adequate site selection. &OLQLFDO7ULDO$JUHHPHQW A Clinical Trial Agreement shall be in place, signed by the par ticipating investigation site and/or principal investigator of each investigati on site, as per the local legal requirements, and returned to Medtronic prior to the commencement of any study activities. The investig ator is indicating approval of the Clinical Investigation Plan and subsequent amendments, by a fully execut ed agreement. &XUULFXOXP9LWDH A curriculum vitae from each Investigator part icipating in the study shall be obtained. 0RQLWRULQJ Medtronic is responsible for ens uring the proper conduct of thi s study in terms of adherence to applicable regulations, protocol compliance, and the validity a nd accuracy of the study data entered on CRFs. The Principal Investigato r, his/her delegate(s) and the study coordinator(s) shall be accessible to Medtronic field personnel and t he Clinical Study Manager. The P rincipal Investigator and site personnel will provide the Medtronic moni tor(s) with complete access to p rimary source data o r certified copies (e.g., paper and electronic hospi tal/clinical charts, appointme nt books, laboratory r ecords) that support the data on the CRFs as well as other documentation supporting the conduct of the study. The monitor"
54,page_54,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 54 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  will perform source data verification and routine reviews of st udy-related regulatory documents during scheduled monitoring visits and wo rk to secure compliance shoul d any deficiencies be observed. The monitoring plan contains the str ategy for frequency of monitori ng visits and source d ata verification to be performed for this study. 0HGWURQLF5HSUHVHQWDWLYH5ROH Medtronic representatives may pa rticipate in the conduct of the study to the extent listed below. Medtronic representatives can pr ovide technical support to the investigator and other health care personnel as needed during study visits. This support may incl ude the training of site personnel on use of the Medtronic equipment or the protocol-related procedures a nd forms. In addition, Medtronic personnel can perform certain activities to ensure study quality. These activities may include: xObserving testing or medical procedures to provide information relevant to protocol completion xReviewing collected data and study documentation for completene ss and accuracy xPerform device programming or device interrogation under the di rection of the investigator(s) Medtronic personnel will not: xPractice medicine xProvide medical diagnosis or treatment to subjects xDiscuss a subject‚Äôs condition or treatment with a subject witho ut the approval and presence of the health care provider. xComplete CRFs or make entries in the subject‚Äôs medical record 'DWD0DQDJHPHQW Medtronic personnel will perform routine edit and consistency c hecks for items such as missing data or inconsistent data. Identified data inconsistencies will be res olved by use of data discrepancies; investigators and site personnel will review data discrepancies and respond to the discrepancies in a timely manner. The resolved disc repancy will become a part of the eCRF record for the subject. The Oracle Clinical Remote Data Capture (RDC) system which is 2 1CFR¬ß11 Part E compliant controls user access, and ensures data integrit y. This system is a fully vali dated system. The RDC system maintains an audit trail of entries, changes or corrections in eCRFs. User a ccess will be granted to each individual based on his or her delegation o f authority and completion of r equired training. If a person only authorized to complete eCRFs mak es changes to an already signed eCRF, the system will require the Principal Investigator, or authorized delegate, to re-sign the eCRF."
55,page_55,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 55 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  The Principal Investigator, or d esignated representative, is re sponsible for the data submitted and must review all data for accuracy and provide his/her approval of th e eCRF and sign each form with an electronic signature. 'LUHFW$FFHVVWR6RXUFH'DWD'RFXPHQWV Source data is all information, o riginal records (or certified copies) of clinical findings, observations or other activities in a study necessary for the reconstruction an d evaluation of the study. Examples of these originaldocuments and reco rds include, but are not limite d to: hospital/clinic records, phone records, laboratory reports, etc . Site personnel should clear ly indicate the subjects‚Äô participate in the study within the medical records. Principal Investigator and Institution must permit study-relate d monitoring, audits , IRB/EC review and regulatory inspections(s) by pro viding direct access to source data/documents. Medtronic or third-party auditors representing Medtronic may perform clinical site audit s to verify the performance of the monitoring process and study co nduct, and to ensure compliance with applicable regulations. Representatives for regulatory b odies such as the FDA may also perform site inspections related to this clinical study. The Principal I nvestigator, site personnel, an d institution will provide auditors with direct access to primary source data and all study-related documentati on. In accordance with GCP and regula tory requirements, Medtronic w ill investigate suspected cases of fraud.  &RQILGHQWLDOLW\ Subject confidentiality is assur ed through the use of subject i dentification numbers, and the de- identifying of photocopied or reco rds obtained by the Sponsor. In addition to the review of records on site, release of de-identified records to Medtronic may be nece ssary, such as in the evaluation of adverse events. For purposes of monitoring this s tudy, access to clinic and hos pital records must be available to Medtronic, agents of Medtronic (e.g. CRO), the FDA, and other r egulatory agencies. Health Insurance Portability and Accountability Act (HIPAA) lan guage will be required to be included at every site in the US. HIPAA language may be included within th e US ICF template."
56,page_56,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 56 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  /LDELOLW\  6WXG\)XQGLQJ The costs associated with study c onduct will be documented in s eparate Clinical Trial Agreements that will be signed by Medtronic, the Principal Investigator, and/or the management of the institution. Subject compensation (if applicable) is detailed in the Patient Informed Consent Form.  ,QVXUDQFH Medtronic of Canada, Lt d., Medtronic International Trading SARL , and Medtronic Logistics LLC are wholly owned subsidiaries of Medt ronic, which as the parent com pany of such entities maintains appropriate clinical study liab ility insurance coverage as requ ired under applicable laws and regulations and will comply with applicable l aw and custom concerning speci fic insurance coverage. If required, a Clinical Trial Insurance statement/certificate will be provided to the EC, governing regulatory authority (if applicable) and/or the IRB.  :DUUDQW\ Warranty information is provided in the product packaging for c ommercially available products.  ,QGHPQLILFDWLRQ Indemnification language will be contained in the Clinical Tria l Agreements. &,3$PHQGPHQWV Protocol amendments may be initi ated by Medtronic to address ch anges to the conduct of the study. Protocol amendments must be approved by Medtronic and submitted to the IRB/EC and governing regulatory authority (if applicab le); protocol amendment approv al and approval of any associated changes to the informed consent document must be obtained prior to implementation of the amendment except: xWhen necessary to eliminate an immediate/or apparent immediate hazard to participating subjects xWhen the change involves purely administrative or logistical as pects of the study  5HFRUG5HWHQWLRQ At a minimum, the investigator i s responsible for the preparati on, review, and retention of the records listed below: xEssential correspondence that p ertains to the investigation"
57,page_57,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 57 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  xRecords of each subject‚Äôs case h istory and exposure to the devi ce. Case histories include the CRFs and supporting data (sour ce documentation), such as: R Signed and dated ICFs R Medical records, including, for example, progress notes of the physicians, the subject‚Äôs hospital chart (s) and the nurses notes R All reportable adverse event information R Data related to the SNM therapy session xDocumentation of any deviation to the protocol, including the d ate and the rati onale for such deviation xSigned Investigator Agreement and curriculum vitae for all Inve stigators xThe protocol and any amendments The Principal Investigator is re sponsible for ensuring that all essential study documentation is retained and accessible for a minimum of 2 years following completion of the study or longer i f required per local regulations. Medtronic will be n otified in writing of any tran sfer of study documentation. 3XEOLFDWLRQDQG8VHRI,QIRUPDWLRQ This feasibility study will provid e an initial understanding of various amplitude stimulation settings and impact on symptoms. The study will be registered on clinicaltr ials.gov and the results of the study may be published. 6XVSHQVLRQRU(DUO\7HUPLQDWLRQ Medtronic reserves the right to suspend or terminate the study at any time. Reasons may include, but are not limited to, the following: xInsufficient enrollment to complete the study within the expect ed timeframe xIdentification of unacceptable sa fety profile; suspicion of an unacceptable risk will result in a suspension, confirmation of an unacceptable risk will result in termination xProduct performance/product supply issues Medtronic reserves the right to suspend or terminate the study at an individual site. Reasons may include, but are not limited to, the following: xNoncompliance with the protocol xSerious or repeated deviations at the site xFailure to implement required corrective and preventive actions xInsufficient enrollment to compl ete the study wi thin the expect ed timeframe xLoss of appropriately trained site personnel"
58,page_58,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 58 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  Investigators are required to not ify the IRB/EC and governing r egulatory authority (if applicable) of study suspension/termination. Subjects will be notified by the inves tigator of suspension/termination due to unacceptable risk or of termination due to any other cause."
59,page_59,",QWHU6WLP$PSOLWXGH&OLQLFDO,QYHVWLJDWLRQ3ODQ  MDT17030 Version 2.0 Page 59 of 61 00HGWURQLF&RQILGHQWLDO  )Y&OLQLFDO,QYHVWLJDWLRQ3ODQ7HPSODWH  5HIHUHQFHV 1. Siegel SW, Catanzaro F, Dijkema HE, Elhilali MM, Fowler CJ, Gajewski JB, Hassouna MM, Jonas U, van Kerrebroeck PE, Lycklama a Ni jeholt AA, Oleson KA, Schmidt RA. Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retent ion. Urology 56: 87-91. 2000. 2. Noblett K, Benson K, and Kred er K. Detailed analysis of adve rse events and surgical Interventions in a large prospective trial of sacral neuromodulation therapy for Overactive bladder patients. Neurourology Urodynamics 36:1136-1139. 2017. 3. Duelund-Jakobsen J, Buntzen S, Lundby, Laurberg S. Sacral ne rve stimulation at subsensory threshold does not compromise tr eatment efficacy: results from a randomized, blinded crossover study. Ann Surg 257: 219-223. 2013. 4. Gleason JL, Kenton K, Greer WJ, Ramm O, Szychowski JM, Wilso n T, Richter HE. Sacral neuromodulation effects on periurethral sensation and urethral sphincter activity. Neurourology Urodynamics. 32(5):476-9. 2013. 5. h≈Ø∆µƒöƒÇ≈íKÕï<≈Ωƒê≈ö^DÕïs≈Ø≈ùƒû≈êƒû≈∂Z&Õïƒû≈©≈Ω≈∂≈ê,Õï«ÄƒÇ≈∂'ƒû≈µƒû∆å∆öt'ÕïƒÇƒû∆öƒû≈∂ 'Õò Sacral neuromodulation: does it affect the rectoanal angle in patients with fecal incontinence? World J Surg. 34(5):1109-14. 2010. 6. Su X, Nickles A, Nelson DE. Optimization of Neuromodulation for Bladder Control in a Rat Cystitis Model. Am J Physiol Renal Physiol 302: F477-486. 2012a. 7. Snellings AE and Grill WM. Effects of stimulation site and s timulation parameters on bladder inhibition by electrical nerve stimulation. BJU Int 110: 136-14 3. 2012. 8. Gill B, Pizarro-Berdichevsky J, Bhattacharyya P, Brink TS, M arks B, Quirouet A, Vasavada, S, Jones SE and Goldman HB. Real-time changes in brain activity during sacral neuromodulation for overactive bladder. J Urol, In Review. 2017. 9. Coyne, K., Revicki, D., Hunt, T ., Corey, R., Stewart, W., Be ntkover, J., Kurth , H., Abrams, P. Psychometric validation of an ov eractive bladder symptom and he alth-related quality of life questionnaire: the OAB-q. Qual.Life.Res. 2002; 11(6); 563-574. 10.Vecchioli-Scaldazza C, Morosetti C, Berouz A, Giannubilo W, Fer rara V. Solifenacin succinate versus percutaneous tibial nerve stimulation in women with over active bladder syndrome: Results of a randomized controll ed crossover study. Gynecologic and Obstetric Investigation 2013; 75(4):230-234."
60,page_60,
61,page_61,
